Tectonic Therapeutic, Inc.
TECX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001681087
In the last 90 days, Tectonic Therapeutic, Inc. insiders filed 0 open-market purchases and 2 sales; 122 institutions reported holding it in 13F filings for Q2 2026, worth $479.9M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Tectonic Therapeutic, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- −7 vs. Q1 2023
- Shares held
- 19.9M
- −2.91M (−12.7%) vs. Q1 2023
- Total value
- $18.9M
- −$3.90M (−17.1%) vs. Q1 2023
- New holders
- 5
- 9 more added
- Sold out
- 12
- 11 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TECX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 122 | $479.9M |
| Q1 2026 | 111 | $426.8M |
| Q4 2025 | 105 | $288.1M |
| Q3 2025 | 99 | $189.9M |
| Q2 2025 | 82 | $240.7M |
| Q1 2025 | 78 | $198.8M |
| Q4 2024 | 70 | $354.9M |
| Q3 2024 | 53 | $217.4M |
| Q2 2024 | 40 | $88.1M |
| Q1 2024 | 47 | $35.2M |
| Q4 2023 | 45 | $32.2M |
| Q3 2023 | 48 | $39.9M |
| Q2 2023 | 41 | $18.9M |
| Q1 2023 | 48 | $22.8M |
| Q4 2022 | 45 | $14.8M |
| Q3 2022 | 54 | $15.7M |
| Q2 2022 | 64 | $23.8M |
| Q1 2022 | 81 | $38.8M |
| Q4 2021 | 94 | $134.9M |
| Q3 2021 | 101 | $166.5M |
| Q2 2021 | 97 | $287.7M |
| Q1 2021 | 99 | $423.5M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Tectonic Therapeutic, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 2 | $2 | 0.00% | −829−99.8% | Reduced |
| UBS Group AG | 65 | $62 | 0.00% | 00.0% | Unchanged |
| National Bank of Canada | 380 | $361 | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 1,208 | $1.15K | 0.00% | +1,208 | New |
| Royal Bank of Canada | 2,325 | $2.00K | 0.00% | +460+24.7% | Added |
| BNP Paribas Arbitrage, SA | 2,994 | $2.85K | 0.00% | −92−3.0% | Reduced |
| CWM, LLC | 6,388 | $6.00K | 0.00% | +4,388+219.4% | Added |
| Commonwealth Equity Services, LLC | 11,000 | $10.0K | 0.00% | +11,000 | New |
| Tower Research Capital LLC (TRC) | 11,955 | $11.4K | 0.00% | +5,600+88.1% | Added |
| C2C Wealth Management, LLC | 10,000 | $15.1K | 0.00% | 00.0% | Unchanged |
| HSBC Holdings PLC | 16,556 | $15.1K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 16,788 | $15.9K | 0.00% | 00.0% | Unchanged |
| Colonial River Wealth Management, LLC | 16,940 | $16.1K | 0.01% | 00.0% | Unchanged |
| Virtu Financial LLC | 22,552 | $21.0K | 0.00% | −17,767−44.1% | Reduced |
| Barclays PLC | 22,179 | $21.1K | 0.00% | +244+1.1% | Added |
| Boothbay Fund Management, LLC | 26,896 | $25.6K | 0.00% | +26,896 | New |
| Deutsche Bank AG | 35,000 | $33.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 75,281 | $71.5K | 0.00% | −184−0.2% | Reduced |
| Privium Fund Management (UK) Ltd | 87,770 | $78.2K | 0.06% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 106,000 | $100.7K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 134,146 | $127.5K | 0.04% | +134,146 | New |
| State Street Corp | 140,852 | $133.8K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 141,759 | $134.7K | 0.00% | −66,220−31.8% | Reduced |
| Wells Fargo & Company | 167,094 | $158.8K | 0.00% | +30,030+21.9% | Added |
| Millennium Management LLC | 181,590 | $172.5K | 0.00% | +6,051+3.4% | Added |
| BML Capital Management, LLC | 256,277 | $243.5K | 0.22% | +256,277 | New |
| Two Sigma Advisers, LP | 257,200 | $244.4K | 0.00% | −74,900−22.6% | Reduced |
| Boston Private Wealth LLC | 284,365 | $270.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 285,861 | $271.6K | 0.00% | −47,137−14.2% | Reduced |
| Geode Capital Management, LLC | 343,741 | $326.6K | 0.00% | +13,229+4.0% | Added |
| Citadel Advisors LLC | 506,354 | $481.1K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 562,567 | $534.0K | 0.00% | −10,800−1.9% | Reduced |
| BlackRock Inc. | 633,036 | $601.4K | 0.00% | −760,333−54.6% | Reduced |
| Farallon Capital Management, L.L.C. | 899,700 | $854.8K | 0.01% | −2,216,300−71.1% | Reduced |
| Aisling Capital Management LP | 1,009,779 | $959.4K | 0.47% | 00.0% | Unchanged |
| Morgan Stanley | 1,049,270 | $996.9K | 0.00% | +846,425+417.3% | Added |
| Vanguard Group Inc | 1,181,134 | $1.12M | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,770,147 | $1.68M | 0.01% | 00.0% | Unchanged |
| GMT Capital Corp | 2,412,015 | $2.29M | 0.09% | −1,945,844−44.7% | Reduced |
| Tang Capital Management LLC | 2,705,000 | $2.57M | 0.38% | +2,667,387+7,091.7% | Added |
| Atlas Venture Life Science Advisors, LLC | 4,541,381 | $4.31M | 0.54% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −650,000−100.0% | Sold out |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −647,918−100.0% | Sold out |
| New Leaf Venture Partners, L.L.C. | 0 | $0 | 0.00% | −315,550−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −45,492−100.0% | Sold out |
| Needham Investment Management LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −26,250−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −24,409−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −19,607−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −1,515−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −725−100.0% | Sold out |